Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%

BUENA, N.J., April 17, 2018 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Cream USP, 0.05%.  This is Teligent’s fourth approval for 2018, and its twenty-third approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Share this post